Other chemokine receptors, including CCR5 and CCR9, which regulate T-ALL proliferation and migration in vitro, are known to be transcriptionally regulated by NOTCH1 and could be likewise considered optimal T-ALL therapeutic targets. This evidence concerns the gene CCR9 and acute lymphoblastic leukemia.